Loading market movers...

Rivastigmine

Phase 3

NOVARTIS AG (NVSEF)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

9

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Vascular Dementia

View Full Landscape

Drug Information

Target Indication

Vascular Dementia

Clinical Trial

Last updated: 2/26/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA4/3/2014

Rivastigmine 3M Health Care Ltd

Symptomatic treatment of mild to moderately severe Alzheimer's dementia.

EMA6/16/2011

Rivastigmine Actavis

Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.

EMA12/11/2009

Rivastigmine 1 A Pharma

Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.

EMA12/11/2009

Rivastigmine Hexal

Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.

EMA12/10/2009

Rivastigmine Sandoz

Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.

EMA5/11/2009

Nimvastid

Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.

EMA4/17/2009

Rivastigmine Teva

Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.

EMA12/4/1998

Prometax

Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.

EMA5/11/1998

Exelon

Symptomatic treatment of mild to moderately severe Alzheimer's dementia. Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.

Drug Science

Mechanism of action & safety profile

Developer

NVSEF

NOVARTIS AG

Biotechnology•North America•NASDAQ

Related Pipeline

FingolimodPhase 3

Multiple Sclerosis

dovitinibPhase 3

Solid Tumors

MF59-eH1N1_fPhase 3

Influenza

Glycopyrronium bromidePhase 3

Chronic Obstructive Pulmonary Disease

Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccinePhase 3

Swine-Origin Influenza A H1N1 Virus

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts